Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36

1.

Temporal Requirement for Pulmonary Resident and Circulating T Cells during Virulent Francisella tularensis Infection.

Roberts LM, Wehrly TD, Ireland RM, Crane DD, Scott DP, Bosio CM.

J Immunol. 2018 Aug 15;201(4):1186-1193. doi: 10.4049/jimmunol.1800052. Epub 2018 Jul 6.

2.

The Ability to Acquire Iron Is Inversely Related to Virulence and the Protective Efficacy of Francisella tularensis Live Vaccine Strain.

Fletcher JR, Crane DD, Wehrly TD, Martens CA, Bosio CM, Jones BD.

Front Microbiol. 2018 Apr 4;9:607. doi: 10.3389/fmicb.2018.00607. eCollection 2018.

3.

Expansion and retention of pulmonary CD4+ T cells after prime boost vaccination correlates with improved longevity and strength of immunity against tularemia.

Roberts LM, Wehrly TD, Crane DD, Bosio CM.

Vaccine. 2017 May 2;35(19):2575-2581. doi: 10.1016/j.vaccine.2017.03.064. Epub 2017 Mar 31.

PMID:
28372827
4.

Inclusion of Epitopes That Expand High-Avidity CD4+ T Cells Transforms Subprotective Vaccines to Efficacious Immunogens against Virulent Francisella tularensis.

Roberts LM, Crane DD, Wehrly TD, Fletcher JR, Jones BD, Bosio CM.

J Immunol. 2016 Oct 1;197(7):2738-47. doi: 10.4049/jimmunol.1600879. Epub 2016 Aug 19.

5.

Metabolic Reprogramming of Host Cells by Virulent Francisella tularensis for Optimal Replication and Modulation of Inflammation.

Wyatt EV, Diaz K, Griffin AJ, Rasmussen JA, Crane DD, Jones BD, Bosio CM.

J Immunol. 2016 May 15;196(10):4227-36. doi: 10.4049/jimmunol.1502456. Epub 2016 Mar 30.

6.

Successful protection against tularemia in C57BL/6 mice is correlated with expansion of Francisella tularensis-specific effector T cells.

Griffin AJ, Crane DD, Wehrly TD, Bosio CM.

Clin Vaccine Immunol. 2015 Jan;22(1):119-28. doi: 10.1128/CVI.00648-14. Epub 2014 Nov 19.

7.

Mitochondrial ROS potentiates indirect activation of the AIM2 inflammasome.

Crane DD, Bauler TJ, Wehrly TD, Bosio CM.

Front Microbiol. 2014 Aug 20;5:438. doi: 10.3389/fmicb.2014.00438. eCollection 2014.

8.

Alternative activation of macrophages and induction of arginase are not components of pathogenesis mediated by Francisella species.

Griffin AJ, Crane DD, Wehrly TD, Scott DP, Bosio CM.

PLoS One. 2013 Dec 6;8(12):e82096. doi: 10.1371/journal.pone.0082096. eCollection 2013.

9.

Lipids derived from virulent Francisella tularensis broadly inhibit pulmonary inflammation via toll-like receptor 2 and peroxisome proliferator-activated receptor α.

Crane DD, Ireland R, Alinger JB, Small P, Bosio CM.

Clin Vaccine Immunol. 2013 Oct;20(10):1531-40. doi: 10.1128/CVI.00319-13. Epub 2013 Aug 7.

10.

B1a cells enhance susceptibility to infection with virulent Francisella tularensis via modulation of NK/NKT cell responses.

Crane DD, Griffin AJ, Wehrly TD, Bosio CM.

J Immunol. 2013 Mar 15;190(6):2756-66. doi: 10.4049/jimmunol.1202697. Epub 2013 Feb 1.

11.

Low dose vaccination with attenuated Francisella tularensis strain SchuS4 mutants protects against tularemia independent of the route of vaccination.

Rockx-Brouwer D, Chong A, Wehrly TD, Child R, Crane DD, Celli J, Bosio CM.

PLoS One. 2012;7(5):e37752. doi: 10.1371/journal.pone.0037752. Epub 2012 May 25.

12.

Generation of a convalescent model of virulent Francisella tularensis infection for assessment of host requirements for survival of tularemia.

Crane DD, Scott DP, Bosio CM.

PLoS One. 2012;7(3):e33349. doi: 10.1371/journal.pone.0033349. Epub 2012 Mar 12.

13.

Long lived protection against pneumonic tularemia is correlated with cellular immunity in peripheral, not pulmonary, organs.

Anderson RV, Crane DD, Bosio CM.

Vaccine. 2010 Sep 14;28(40):6562-72. doi: 10.1016/j.vaccine.2010.07.072. Epub 2010 Aug 3.

14.

A novel role for plasmin-mediated degradation of opsonizing antibody in the evasion of host immunity by virulent, but not attenuated, Francisella tularensis.

Crane DD, Warner SL, Bosio CM.

J Immunol. 2009 Oct 1;183(7):4593-600. doi: 10.4049/jimmunol.0901655. Epub 2009 Sep 14.

15.

Chlamydia trachomatis native major outer membrane protein induces partial protection in nonhuman primates: implication for a trachoma transmission-blocking vaccine.

Kari L, Whitmire WM, Crane DD, Reveneau N, Carlson JH, Goheen MM, Peterson EM, Pal S, de la Maza LM, Caldwell HD.

J Immunol. 2009 Jun 15;182(12):8063-70. doi: 10.4049/jimmunol.0804375.

16.

Intracellular biology and virulence determinants of Francisella tularensis revealed by transcriptional profiling inside macrophages.

Wehrly TD, Chong A, Virtaneva K, Sturdevant DE, Child R, Edwards JA, Brouwer D, Nair V, Fischer ER, Wicke L, Curda AJ, Kupko JJ 3rd, Martens C, Crane DD, Bosio CM, Porcella SF, Celli J.

Cell Microbiol. 2009 Jul;11(7):1128-50. doi: 10.1111/j.1462-5822.2009.01316.x. Epub 2009 Mar 18.

17.

The Chlamydia trachomatis plasmid is a transcriptional regulator of chromosomal genes and a virulence factor.

Carlson JH, Whitmire WM, Crane DD, Wicke L, Virtaneva K, Sturdevant DE, Kupko JJ 3rd, Porcella SF, Martinez-Orengo N, Heinzen RA, Kari L, Caldwell HD.

Infect Immun. 2008 Jun;76(6):2273-83. doi: 10.1128/IAI.00102-08. Epub 2008 Mar 17.

18.

Pathogenic diversity among Chlamydia trachomatis ocular strains in nonhuman primates is affected by subtle genomic variations.

Kari L, Whitmire WM, Carlson JH, Crane DD, Reveneau N, Nelson DE, Mabey DC, Bailey RL, Holland MJ, McClarty G, Caldwell HD.

J Infect Dis. 2008 Feb 1;197(3):449-56. doi: 10.1086/525285.

PMID:
18199030
19.

Chlamydia trachomatis species-specific induction of ezrin tyrosine phosphorylation functions in pathogen entry.

Swanson KA, Crane DD, Caldwell HD.

Infect Immun. 2007 Dec;75(12):5669-77. Epub 2007 Oct 1.

20.

Phenotypic rescue of Chlamydia trachomatis growth in IFN-gamma treated mouse cells by irradiated Chlamydia muridarum.

Nelson DE, Taylor LD, Shannon JG, Whitmire WM, Crane DD, McClarty G, Su H, Kari L, Caldwell HD.

Cell Microbiol. 2007 Sep;9(9):2289-98. Epub 2007 May 15.

PMID:
17501981
21.

Chlamydia trachomatis polymorphic membrane protein D is a species-common pan-neutralizing antigen.

Crane DD, Carlson JH, Fischer ER, Bavoil P, Hsia RC, Tan C, Kuo CC, Caldwell HD.

Proc Natl Acad Sci U S A. 2006 Feb 7;103(6):1894-9. Epub 2006 Jan 30.

22.

Inhibition of chlamydiae by primary alcohols correlates with the strain-specific complement of plasticity zone phospholipase D genes.

Nelson DE, Crane DD, Taylor LD, Dorward DW, Goheen MM, Caldwell HD.

Infect Immun. 2006 Jan;74(1):73-80.

23.

Chlamydial IFN-gamma immune evasion is linked to host infection tropism.

Nelson DE, Virok DP, Wood H, Roshick C, Johnson RM, Whitmire WM, Crane DD, Steele-Mortimer O, Kari L, McClarty G, Caldwell HD.

Proc Natl Acad Sci U S A. 2005 Jul 26;102(30):10658-63. Epub 2005 Jul 14.

24.
25.

Chlamydial infection induces pathobiotype-specific protein tyrosine phosphorylation in epithelial cells.

Virok DP, Nelson DE, Whitmire WM, Crane DD, Goheen MM, Caldwell HD.

Infect Immun. 2005 Apr;73(4):1939-46.

26.

Transcriptome analysis of chlamydial growth during IFN-gamma-mediated persistence and reactivation.

Belland RJ, Nelson DE, Virok D, Crane DD, Hogan D, Sturdevant D, Beatty WL, Caldwell HD.

Proc Natl Acad Sci U S A. 2003 Dec 23;100(26):15971-6. Epub 2003 Dec 12.

27.

Genomic transcriptional profiling of the developmental cycle of Chlamydia trachomatis.

Belland RJ, Zhong G, Crane DD, Hogan D, Sturdevant D, Sharma J, Beatty WL, Caldwell HD.

Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8478-83. Epub 2003 Jun 18.

28.

Chlamydia trachomatis cytotoxicity associated with complete and partial cytotoxin genes.

Belland RJ, Scidmore MA, Crane DD, Hogan DM, Whitmire W, McClarty G, Caldwell HD.

Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13984-9. Epub 2001 Nov 13.

29.
30.

The 16-kDa alpha-crystallin (Acr) protein of Mycobacterium tuberculosis is required for growth in macrophages.

Yuan Y, Crane DD, Simpson RM, Zhu YQ, Hickey MJ, Sherman DR, Barry CE 3rd.

Proc Natl Acad Sci U S A. 1998 Aug 4;95(16):9578-83.

31.

Inhibition of a Mycobacterium tuberculosis beta-ketoacyl ACP synthase by isoniazid.

Mdluli K, Slayden RA, Zhu Y, Ramaswamy S, Pan X, Mead D, Crane DD, Musser JM, Barry CE 3rd.

Science. 1998 Jun 5;280(5369):1607-10.

33.
34.
35.

Acyclovir treatment of varicella in otherwise healthy children.

Balfour HH Jr, Kelly JM, Suarez CS, Heussner RC, Englund JA, Crane DD, McGuirt PV, Clemmer AF, Aeppli DM.

J Pediatr. 1990 Apr;116(4):633-9.

PMID:
2156984
36.

Laboratory studies of acute varicella and varicella immune status.

Balfour HH Jr, Edelman CK, Dirksen CL, Palermo DR, Suarez CS, Kelly J, Kentala JT, Crane DD.

Diagn Microbiol Infect Dis. 1988 Jul;10(3):149-58.

PMID:
2852574

Supplemental Content

Loading ...
Support Center